Noriaki Ohuchi

Noriaki Ohuchi

Auto-generated profile, based on publicly available information

Noriaki Ohuchi

Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in The Lancet
Verified
Journal Article
Closed access
NONoriaki Ohuchi
Noriaki Ohuchi
ASAkihiko Suzuki
Akihiko Suzuki
TSTomotaka Sobue
Tomotaka Sobue
MKMasaaki Kawai
Masaaki Kawai
SYSeiichiro Yamamoto
Seiichiro Yamamoto
TITakanori Ishida
Takanori Ishida

4 September 2015 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
MMMinoru みやした Miyashita
Minoru みやした Miyashita
HSHironobu Sasano
Hironobu Sasano
KTKentaro Tamaki
Kentaro Tamaki
HHHisashi Hirakawa
Hisashi Hirakawa
YTYayoi Takahashi
Yayoi Takahashi
TITakanori Ishida
Takanori Ishida
The status of tumor-infiltrating lymphocytes (TILs) has been recently proposed to predict clinical outcome of patients with breast cancer. We therefore studied the prognostic significance of CD8+ TILs and FOXP3+ TILs in residual tumors after neoadjuvant chemotherapy (NAC) and the alterations in these parameters before and after NAC in patients with triple-negative breast cancer (TNBC). One hundred thirty-one TNBC patients who received NAC at three institutions were examined. CD8+ TIL and FOXP3+ TIL in residual tumors and biopsy specimens were evaluated by double-staining immunohistochemistry. The CD8+ TIL and FOXP3+ TIL status of the residual tumors was assessed, and the rates of their changes before and after NAC were calculated. TNBC patients with high CD8+ TIL levels or a high CD8/FOXP3 ratio in residual tumors had significantly better recurrence-free survival (RFS) and breast cancer-specific survival (BCSS) than patients with low values of these parameters. In multivariate analyses, CD8+ TIL exhibited strong prognostic significance for RFS, with a hazard ratio (HR) of 3.09 (95 % confidence interval (CI) 1.537–6.614, P=0.0013). The CD8/FOXP3 ratio was also significantly correlated with RFS (HR=2.07, 95 % CI 1.029–4.436, P=0.0412). TNBC with larger residual tumor size and positive lymph node status, which are known prognostic factors, was independently associated with worse RFS (P=0.0064 and P=0.0015, respectively). High CD8+ TIL levels were a markedly powerful indicator of improved BCSS, with an HR of 3.59 (95 % CI 1.499–9.581, P=0.0036). Nodal status was also associated with BCSS (P=0.0024). TNBC with a high rate of CD8+ TIL changes was associated with significantly better RFS compared with the low group (P=0.011). Higher rates of changes in the CD8/FOXP3 ratio were significantly correlated with both better RFS and BCSS compared with lower rates (P=0.011 and P=0.023, respectively). This is the first study to demonstrate that high CD8+ TIL and a high CD8/FOXP3 ratio in residual tumors and increment of these parameters following NAC and accurately predict improved prognosis in TNBC patients with non-pathological complete response following NAC. These parameters could serve as a surrogate one for adjuvant treatment in patients with residual disease in the neoadjuvant setting.

2 August 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
NHNarumi Harada-Shoji
Narumi Harada-Shoji
ASAkihiko Suzuki
Akihiko Suzuki
TITakanori Ishida
Takanori Ishida
YZYing-Fang Zheng
Ying-Fang Zheng
YNYoko Narikawa-Shiono
Yoko Narikawa-Shiono
NONoriaki Ohuchi
Noriaki Ohuchi
Globally, breast cancer is the most frequently diagnosed cancer and is the leading cause of cancer-related death in women.1 In Japan, breast cancer is also the leading cancer in women, with breast cancer incidence rates peaking among women aged 45 to 49 years.2 Mammography is the only screening modality that has been shown to be associated with reduced deaths caused by breast cancer. However, the sensitivity of mammography is variable and ranges from as high as 80% to 98% in women with fatty breast tissue to as low as 30% to 48% in women with dense breast tissue.3,4 Because of the limitations of mammography and increase in breast cancer awareness, a few study groups have investigated the performance characteristics of supplementary screening tools, including breast ultrasonography, tomosynthesis, and magnetic resonance imaging.5-8

12 January 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
HUHajime Uchida
Hajime Uchida
MMMasakazu Machida
Masakazu Machida
TMTakumi Miura
Takumi Miura
TKTomoyuki Kawasaki
Tomoyuki Kawasaki
TOTakuya Okazaki
Takuya Okazaki
HAHidenori Akutsu
Hidenori Akutsu
Functional intestines are composed of cell types from all 3 primary germ layers and are generated through a highly orchestrated and serial developmental process. Directed differentiation of human pluripotent stem cells (hPSCs) has been shown to yield gut-specific cell types; however, these structures do not reproduce critical functional interactions between cell types of different germ layers. Here, we developed a simple protocol for the generation of mature functional intestinal organoids from hPSCs under xenogeneic-free conditions. The stem cell–derived gut organoids produced here were found to contain distinct types of intestinal cells, including enterocytes, goblet cells, Paneth cells, and enteroendocrine cells, that were derived from all 3 germ layers; moreover, they demonstrated intestinal functions, including peptide absorption, and showed innervated bowel movements in response to stimulation with histamine and anticholinergic drugs. Importantly, the gut organoids obtained using this xenogeneic-free system could be stably maintained in culture for prolonged periods and were successfully engrafted in vivo. Our xenogeneic-free approach for generating gut organoids from hPSCs provides a platform for studying human intestinal diseases and for pharmacological testing.

1 March 2001 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
RYRyuichi Yoshida
Ryuichi Yoshida
NKNORIKO KIMURA
NORIKO KIMURA
YHY. Harada
Y. Harada
NON. Ohuchi
N. Ohuchi
Loss of E-cadherin and catenin expression may be associated with distant and lymph node metastases in breast cancer. Heterogeneity of E-cadherin expression is associated with poor prognosis, suggesting that E-cadherin and catenins may serve as useful prognostic markers for invasive breast carcinoma. Reduction or loss of expression of either E-cadherin or catenins is associated with invasion, metastasis and poor prognosis in several types of human malignancies. We investigated the expression of E-cadherin, and α- and β-catenins by immunohistochemistry in 171 cases of primary invasive breast cancer, and compared the expression with clinicopathological parameters to define the relationship between expression and prognosis. E-cadherin immunoreactive protein was shown to be expressed in 97 cases. Reduction or lack of expression of E-cadherin was associated with distant metastasis. Based on immunohistochemical heterogeneity, E-cadherin-positive tumors were classified into heterogeneous, homogeneous and intermediate types. Interestingly, although patients with heterogeneous type demonstrated the lowest incidence of distant metastasis at diagnosis, they showed a higher incidence of subsequent distant metastasis, after surgery, and a lower survival rate than those with homogeneous type (p<0.05). E-cadherin expression was reduced or negative in metastatic axillary lymph nodes regardless of the expression in the primary tumor, suggesting that changes in E-cadherin expression are associated with not only distant metastasis but also lymph node metastasis. Tumors negative for either α- or β-catenin expression demonstrated a higher incidence of distant metastasis than those expressing both catenins, suggesting that the expression of catenins is involved in breast cancer metastasis. Reduction or loss of E-cadherin and catenin expression may be associated with distant and lymph node metastases in invasive breast cancer, and the heterogeneous type may be associated with poor prognosis.

2 December 2010 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
NONoriaki Ohuchi
Noriaki Ohuchi
TITakanori Ishida
Takanori Ishida
MKMasaaki Kawai
Masaaki Kawai
YNYoko Narikawa
Yoko Narikawa
SYSeiichiro Yamamoto
Seiichiro Yamamoto
TSTomotaka Sobue
Tomotaka Sobue
In cancer screening, it is essential to undertake effective screening with appropriate methodology, which should be supported by evidence of a reduced mortality rate. At present, mammography is the only method for breast cancer screening with such evidence. However, mammography does not achieve sufficient accuracy in breasts with high density at ages below 50. Although ultrasonography achieves better accuracy in Breast Cancer detection even in dense breasts, the effectiveness has not been verified. We have planned a randomized controlled trial to assess the effectiveness of ultrasonography in women aged 40–49, with a design to study 50 000 women with mammography and ultrasonography (intervention group), and 50 000 controls with mammography only (control group). The participants are scheduled to take second round screening with the same modality 2 years on. The primary endpoints are sensitivity and specificity, and the secondary endpoint is the rate of advanced breast cancers.